MSG
LFCR icon

Main Street Group’s Lifecore Biomedical LFCR Stock Holding History

Main Street Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525 Buy
+100
New +$504 ﹤0.01% 777

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Main Street Group's LFCR Position: Q2 2026 in Review

Main Street Group opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 100 shares worth $525. The stake represents ﹤0.01% of the portfolio and ranks #777 among its holdings.

99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Main Street Group held 100 shares of Lifecore Biomedical worth $525 as of Q2 2026.
  • Lifecore Biomedical was a new Main Street Group position in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Main Street Group's portfolio in Q2 2026, its #777 holding.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Main Street Group's 13F filing for Q2 2026, filed 13 Jul 2026.